Formulary Chapter 7: Obstetrics, Gynaecology, and urinary-tract disorders - Full Chapter
|
07.04.05 |
Drugs for erectile dysfunction |
|
|
07.04.05 |
Phosphodiesterase type 5 inhibitors |
|
|
07.04.05 |
Papaverine and phentolamine |
|
|
Sildenafil chewable tablets (Nipatra®)

|
Non Formulary
|
Discontinued October 2017 |
Tadalafil once daily

|
Non Formulary
|
In line with NHS England's Guidance for CCGs: Items which should not routinely be prescribed in primary care (Dec 2017)
Click here to access guidance
|
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
Status |
Description |

|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications. |

|
Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.
Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements. |

|
Medicines for initiation and maintenance prescribing by Specialists only |

|
Non-formulary medicines- medicines not recommended for routine primary care prescribing. |

|
Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information. |
|
|